Pankova O.A., prof. Korzh O.M.

Kharkiv National Medical University

Objective. To investigate the peculiarities of home blood pressure monitoring parameters in patients with essential hypertension (EH) in combination with type 2 diabetes mellitus (T2DM) and to evaluate their relationships with plasma catestatin (CTS) and relaxin-2 (RLN-2) levels. Materials and methods. 106 patients with EH, 55 of whom had comorbidity T2DM, and 30 healthy volunteers were enrolled in the study. Each patient underwent a comprehensive clinical examination, including measurement of systolic (SBP) and diastolic (DBP) blood pressure. Each study subject carried out home blood pressure monitoring for 31 days with the further registration of indicators in a diary. The levels of CTS and RLN-2 were determined by the enzyme-linked immunosorbent assay. Statistical data analysis was performed using the SPSS 25.0 statistical software. Results. CTS levels were reduced in patients with high normal SBP and arterial hypertension (p<0.001). There were revealed significant negative correlations of CTS levels with home blood pressure monitoring parameters (p<0.05). In patients with levels of RLN-2≥4.69 pg/ml, there were observed higher SBP (p<0.001) and DBP (p<0.05) parameters, except average and morning DBP. Conclusions. The decrease in CTS levels in EH and established correlations between CTS and home blood pressure monitoring parameters allow us to consider CTS as a biomarker of EH, especially EH with T2DM.

Key words: essential hypertension, type 2 diabetes mellitus, blood pressure, home blood pressure monitoring, catestatin, relaxin-2.

https://doi.org/10.15407/internalmed2023.02b.103

Download.PDF

Cite:

Панкова, О.А. Взаємозв’язки параметрів домашнього моніторингу артеріального тиску та рівнів катестатину і релаксину-2 у плазмі крові у пацієнтів з гіпертонічною хворобою та цукровим діабетом 2 типу / О.А. Панкова, О.М. Корж // Східноєвропейський журнал внутрішньої та сімейної медицини. – 2023. – № 2(Б). – С. 103-110. doi: 10.15407/internalmed2023.02b.103

Pankova OA, Korzh OM. [Relationships between home blood pressure monitoring parameters and plasma catestatin and relaxin-2 levels in patients with essential hypertension and type 2 diabetes mellitus]. Shidnoevr. z. vnutr. simejnoi med. 2023;2(B):103-110. Ukrainian. doi: 10.15407/internalmed2023.02b.103

References:

1. Chow C. Prevalence, Awareness, Treatment, and Control of Hypertension in Rural and Urban Communities in High-, Middle-, and Low-Income Countries. JAMA. 2013;310(9):959. http://dx.doi.org/10.1001/jama.2013.184182
2. Kearney P, Whelton M, Reynolds K, Muntner P, Whelton P, He J. Global burden of hypertension: analysis of worldwide data. The Lancet. 2005;365(9455):217-223. http://dx.doi.org/10.1016/s0140-6736(05)17741-1
3. Mills K, Stefanescu A, He J. The global epidemiology of hypertension. Nature Reviews Nephrology. 2020;16(4):223-237. http://dx.doi.org/10.1038/s41581-019-0244-2
4. Bozic J, Kumric M, Ticinovic Kurir T, Urlic H, Martinovic D, Vilovic M, Tomasovic Mrcela N, Borovac J. Catestatin as a Biomarker of Cardiovascular Diseases: A Clinical Perspective. Biomedicines. 2021;9(12):1757. http://dx.doi.org/10.3390/biomedicines9121757
5. Aragón-Herrera A, Feijóo-Bandín S, Anido-Varela L, Moraña-Fernández S, Roselló-Lletí E, Portolés M, Tarazón E, Gualillo O, González-Juanatey J, Lago F. Relaxin-2 as a Potential Biomarker in Cardiovascular Diseases. Journal of Personalized Medicine. 2022;12(7):1021. http://dx.doi.org/10.3390/jpm12071021
6. Bathgate R, Halls M, van der Westhuizen E, Callander G, Kocan M, Summers R. Relaxin Family Peptides and Their Receptors. Physiological Reviews. 2013;93(1):405-480. http://dx.doi.org/10.1152/physrev.00001.2012
7. Pankova O, Korzh O. Plasma catestatin levels are related to metabolic parameters in patients with essential hypertension and type 2 diabetes mellitus. Heart and Vessels. 2023;:. http://dx.doi.org/10.1007/s00380-023-02318-w
8. Williams B, Mancia G, Spiering W. 2018 ESC/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of cardiology (ESC) and the European society of hypertension (ESH). Eur Heart J. 2018;39(33):3021–3104. doi: 10.1097/HJH.0000000000001961.
9. Yildiz M, Esenboğa K, Oktay A. Hypertension and diabetes mellitus: highlights of a complex relationship. Current Opinion in Cardiology. 2020;35(4):397-404. http://dx.doi.org/10.1097/hco.0000000000000748
10. O’Connor D, Kailasam M, Kennedy B, Ziegler M, Yanaihara N, Parmer R. Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension.. Journal of Hypertension. 2002;20(7):1335-1345. http://dx.doi.org/10.1097/00004872-200207000-00020
11. Kumric M, Vrdoljak J, Dujic G, Supe-Domic D, Ticinovic Kurir T, Dujic Z, Bozic J. Serum Catestatin Levels Correlate with Ambulatory Blood Pressure and Indices of Arterial Stiffness in Patients with Primary Hypertension. Biomolecules. 2022;12(9):1204. http://dx.doi.org/10.3390/biom12091204
12. Durakoglugil M, Ayaz T, Kocaman S, Kirbas A, Durakoglugil T, Erdogan T, Cetin M, Sahin O, Cicek Y. The relationship of plasma catestatin concentrations with metabolic and vascular parameters in untreated hypertensive patients: Influence on high-density lipoprotein cholesterol. The Anatolian Journal of Cardiology. 2015;15(7):577-585. http://dx.doi.org/10.5152/akd.2014.5536
13. Topal D, Mutluer F, Akgumus A, Er F, Demir M, Tenekecioglu E. Plasma catestatin importance and correlation in patients with dipper and non-dipper hypertension patients. Medicine Science | International Medical Journal. 2022;11(3):1402. http://dx.doi.org/10.5455/medscience.2022.08.191
14. Dunaieva IP, Bilovol OM. Znachennia katestatynu v diahnostytsi sertsevo-sudynnykh i metabolichnykh rozladiv u komorbidnykh patsiientiv z arterialnoiu hipertenziieiu. Mizhnarodnyi endokrynolohichnyi zhurnal. 2023;19(4):319–324. doi: 10.22141/2224-0721.19.4.2023.1293. Ukrainian
15. Papadopoulos D, Makris T, Perrea D, Zerva K, Tsioufis C, Faselis C, Papademetriou V. Apelin and Relaxin Plasma Levels in Young Healthy Offspring of Patients With Essential Hypertension. The Journal of Clinical Hypertension. 2014;16(3):198-201. http://dx.doi.org/10.1111/jch.12260
16. Gedikli O, Yilmaz H, Kiris A, Karaman K, Ozturk S, Baykan M, Ucar U, Durmus I, Karahan C, Celik S. Circulating levels of relaxin and its relation to cardiovascular function in patients with hypertension. Blood Pressure. 2009;18(1-2):68-73. http://dx.doi.org/10.1080/08037050902864086
17. Sanidas E, Tsakalis K, Papadopoulos D. The impact of apelin and relaxin plasma levels in masked hypertension and white coat hypertension. Greenwich. 2019;21(1):48−52. doi: 10.1111/jch.13449.
18. Papadopoulos D, Mourouzis I, Faselis C, Perrea D, Makris T, Tsioufis C, Papademetriou V. Masked Hypertension and Atherogenesis: The Impact of Apelin and Relaxin Plasma Levels. The Journal of Clinical Hypertension. 2013;15(5):333-336. http://dx.doi.org/10.1111/jch.12075